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Abstract. Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that plays a key role in the
pathogenesis of Alzheimer’s disease (AD). GSK3 phosphorylates tau in most serine and threonine residues hyperphosphorylated
in paired helical filaments, and GSK3 activity contributes both to amyloid- production and amyloid--mediated neuronal
death. Thus, mice generated in our laboratory with conditional overexpression of GSK3 in forebrain neurons (Tet/GSK3mice)
recapitulate aspects of AD neuropathology such as tau hyperphosphorylation, apoptotic neuronal death, and reactive astrocytosis,
as well as spatial learning deficit. In this review, we describe recent contributions of our group showing that transgene shutdown
in that animal model leads to normal GSK3 activity, normal phospho-tau levels, diminished neuronal death, and suppression of
the cognitive deficit, thus further supporting the potential of GSK3 inhibitors for AD therapeutics. In addition, we have combined
transgenic mice overexpressing the enzyme GSK3 with transgenic mice expressing tau with a triple FTDP-17 mutation that
develop prefibrillar tau-aggregates. Our data suggest that progression of the tauopathy can be prevented by administration of
lithium when the first signs of neuropathology appear. Further, it is possible to partially reverse tau pathology in advanced stages
of the disease, although the presence of already assembled neurofibrillary tangle-like structures cannot be reversed.
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In 1906, Alois Alzheimer described two aberrant
components found in the brain of a demented patient
after death: senile plaques and neurofibrillary tangles
[1]. In the 1980 s the main components of plaques
(amyloid- (A) peptides) and tangles (tau protein)
were described [2, 3]. By the end of the twentieth cen-
tury, genetic studies discovered a monogenic origin
for the familial form of Alzheimer’s disease (FAD)
[4]. Mutations at specific sites in one of three genes
(APP, PS-1, PS-2) result in the onset of neurodegen-
eration and the appearance of dementia. Since those
three genes codify for proteins related to the generation
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of A peptide, it was suggested that, at least for FAD,
the origin of the disease was the accumulation of A
peptide [5], with tau pathology being a further step in
the development of the disease. In that way, tau pathol-
ogy should be promoted by the accumulation of A
peptides.
Tau pathology in AD is related to tau phosphoryla-
tion and aggregation. The involvement of A peptide
in tau phosphorylation was first tested mostly by look-
ing for the activation of a possible tau kinase upon A
peptide addition. At least one of these tau kinases was
found to be GSK3, based on the fact that lithium, a
GSK3 inhibitor, protects cultured neurons against A-
induced neurodegeneration [6]. Other studies [7–10]
resulted in the same conclusions, and later it was
shown that the production of Apeptide interferes with
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insulin or wnt pathway [11, 12]. Additionally, in the
1990 s, GSK3 (an isoform of GSK3) was identified
as a tau protein kinase I [13] and as such was able to
phosphorylate tau in several sites hyperphosphorylated
in the paired helical filaments present in the tangles of
the brain of AD patients [14–16]. At that time it was
also found that GSK3 accumulates in the cytoplasm
of pretangle neurons, and its distribution in brain for
AD neurofibrillary changes was coincident with the
sequence of development of those changes [17, 18].
Based on the evidence linking A peptide, GSK3
activation, and tau phosphorylation, it was hypothe-
sized that GSK3 deregulation in neurons may be a key
point in the development of AD. Thus, a conditional
transgenic mouse overexpressing GSK3 in the fore-
brain was generated and the characterization of that
mouse showed increased tau phosphorylation in AD
relevant epitopes and neurodegeneration [19]. After-
ward, memory impairment in this transgenic mouse
model [20], which correlated with a clear degeneration
of the dentate gyrus [21], was observed.
Meanwhile, in FAD due to PS-1 mutations, the
increase in A peptide for each mutation did not cor-
relate with the reported age of onset of FAD caused
by that mutation and the appearance of dementia was
not always dependent on A peptide accumulation
[22]. Indeed, it was found that some PS-1 mutations
resulting in the appearance of dementia could activate
GSK3 and promote tau phosphorylation by an alterna-
tive pathway from A peptide, involving cadherin and
PI3K/Akt signaling [23]. Also, other groups’ results
indicated that the presence of tau might be needed for
the induction of A toxicity [24–26]. Thus, GSK3 and
tau phosphorylation could be points of convergence
for the development of dementia initiated in differ-
ent ways, and our conditional transgenic GSK3 mouse
model could be a suitable model to test the effects of
GSK3 overexpression and the possible toxicity of tau
phosphorylated by GSK3. This last point was tested
by analyzing the effect of GSK3 overexpression in a
mouse lacking tau, and the results indicated that an
increase in phospho-tau could be toxic for neurons,
although there are other toxic factors that, in addition
to phospho-tau, could act on a neuron after GSK3 over-
expression [27]. Also, tau hyperphosphorylation and
neurodegeneration resulted in glia activation that was
observed in the mouse overexpressing GSK3 [19, 21].
One important point was to determine if some of these
features could be reversible if GSK3 overexpression
decreased to normal expression level of the kinase.
This was the basis of the work that we highlight in
this review. In this work [28], by using the conditional
Fig. 1. This figure summarizes our studies on the effect of GSK3
activation in hippocampal neurons of a mouse. GSK3 activation
could be activated by overexpression of the protein or by the effect
of other components like the presence of A oligomers or that of
mutated PS-1 at some specific sites. The consequences of activated
GSK3 in a conditional transgenic mouse overexpressing GSK3 in the
hippocampus are indicated. Some of the consequences are reverted
by decreasing GSK3 overexpression in the conditional model. Mem-
ory impairment may be only reverted if remains a population of
neuronal precursors ().
GSK3 mouse model, we found that transgene shut-
down in symptomatic but young mice leads to normal
GSK3 activity, normal phospho-tau levels, diminished
neuronal death, and suppression of the cognitive deficit
(Fig. 1). These points are of interest since they support
the potential use of GSK3 inhibitors for AD therapeu-
tics. However, our analyses were done in young mice,
while AD patients are largely elderly humans. Indeed,
AD symptoms in humans appear after devastating neu-
rodegeneration has already taken place, thus the use
of some therapeutic compounds could be too late for
effective treatment.
To address that question, a double transgenic model
overexpressing GSK3 in a conditional manner [19]
and tau protein carrying three FTDP-17 mutations
[21] was treated with lithium, a widely used drug for
affective disorders which inhibits GSK3 at therapeu-
tically relevant concentrations [29]. This transgenic
line shows tau hyperphosphorylation in hippocam-
pal neurons accompanied by neurofibrillary tangles
(aggregated tau can only be found at the age of 18
months). Chronic lithium treatment, and shutdown
of GSK3 overexpression with doxicycline prevented
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the development of tau pathology when administered
early in disease progression. On the other hand, when
lithium was administered at late stages of disease, it
still reduced tau hyperphosphorylation but could not
reverse tau aggregation [30]. The same result has been
reported in transgenic mice overexpressing FTDP-17
tau in a conditional model and after turning out the
system with doxicycline [25]. Thus, neurofibrillary
tangles seem to be very stable structures, and though
different treatments revert soluble hyperphosphory-
lated tau, NFTs cannot be changed back.
To further analyze this point, we tested the possible
causes of cognitive impairment at different ages in the
GSK3 overexpressing mice [28]. We found degen-
eration in the dentate gyrus of the transgenic mice
[21]. This degeneration was due in part to an aber-
rant neurogenesis known to take place in the dentate
gyrus [31]. Aging of the transgenic mouse correlates
with a decrease in the number of precursor cells that
can become new neurons because there is a depletion
of those precursors in old mice [32]. Our prelimi-
nary data [28, 33] indicate that transgene shutdown
in symptomatic old mice leads to normal GSK3 activ-
ity and normal phospho-tau levels, but cognitive deficit
remains without change. Our current hypothesis is that
in elderly AD patients a similar process takes place.
Likely there is not only degeneration but also absence
of new functional neurons at the time of first diagnosis
of the disease. More work should be done to determine
if this is the case.
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